Related Experiment Video
Updated: Aug 5, 2025

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Cortical iron accumulation in MAPT- and C9orf 72-associated frontotemporal lobar degeneration
Lucia A A Giannini1, Marjolein Bulk1, Boyd Kenkhuis2
1Department of Neurology and Alzheimer Center Erasmus MC, Erasmus MC University Medical Center, Rotterdam, Netherlands.
Abstract:
Neuroinflammation has been implicated in frontotemporal lobar degeneration (FTLD) pathophysiology, including in genetic forms with microtubule-associated protein tau (MAPT) mutations (FTLD-MAPT) or chromosome 9 open reading frame 72 (C9orf72) repeat expansions (FTLD-C9orf72). Iron accumulation as a marker of neuroinflammation has, however, been understudied in genetic FTLD to date. To investigate the occurrence of cortical iron accumulation in FTLD-MAPT and FTLD-C9orf72, iron histopathology was performed on the frontal and temporal cortex of 22 cases (11 FTLD-MAPT and 11 FTLD-C9orf72). We studied patterns of cortical iron accumulation and its colocalization with the corresponding underlying pathologies (tau and TDP-43), brain cells (microglia and astrocytes), and myelination. Further, with ultrahigh field ex vivo MRI on a subset (four FTLD-MAPT and two FTLD-C9orf72), we examined the sensitivity of T2*-weighted MRI for iron in FTLD. Histopathology showed that cortical iron accumulation occurs in both FTLD-MAPT and FTLD-C9orf72 in frontal and temporal cortices, characterized by a diffuse mid-cortical iron-rich band, and by a superficial cortical iron band in some cases. Cortical iron accumulation was associated with the severity of proteinopathy (tau or TDP-43) and neuronal degeneration, in part with clinical severity, and with the presence of activated microglia, reactive astrocytes and myelin loss. Ultra-high field T2*-weighted MRI showed a good correspondence between hypointense changes on MRI and cortical iron observed on histology. We conclude that iron accumulation is a feature of both FTLD-MAPT and FTLD-C9orf72 and is associated with pathological severity. Therefore, in vivo iron imaging using T2*-weighted MRI or quantitative susceptibility mapping may potentially be used as a noninvasive imaging marker to localize pathology in FTLD.
Insights
Iron accumulation is present in genetic frontotemporal lobar degeneration (FTLD) linked to MAPT mutations or C9orf72 expansions. This iron buildup correlates with disease severity and neuroinflammation markers, suggesting potential for MRI-based diagnostics.
Area of Science:
- Neuroscience
- Neuropathology
- Neuroimaging
Background:
- Neuroinflammation is implicated in frontotemporal lobar degeneration (FTLD) pathophysiology.
- Genetic FTLD forms include those with MAPT mutations (FTLD-MAPT) and C9orf72 expansions (FTLD-C9orf72).
- Iron accumulation, a marker of neuroinflammation, has been understudied in genetic FTLD.
Purpose of the Study:
- To investigate cortical iron accumulation in FTLD-MAPT and FTLD-C9orf72.
- To examine the association of iron accumulation with underlying pathologies, cellular changes, and clinical severity.
- To assess the utility of ultra-high field MRI for detecting iron in FTLD.
Main Methods:
- Histopathological analysis of frontal and temporal cortex iron in 22 FTLD cases (11 FTLD-MAPT, 11 FTLD-C9orf72).
- Studied iron colocalization with tau, TDP-43, microglia, astrocytes, and myelination.
- Utilized ultra-high field ex vivo MRI (T2*-weighted) on a subset of cases.
Main Results:
- Cortical iron accumulation was observed in both FTLD-MAPT and FTLD-C9orf72, forming distinct bands.
- Iron accumulation correlated with proteinopathy severity (tau/TDP-43), neuronal degeneration, and clinical severity.
- T2*-weighted MRI showed good correspondence with histologically observed cortical iron.
Conclusions:
- Iron accumulation is a neuropathological feature of both FTLD-MAPT and FTLD-C9orf72.
- Iron burden is associated with pathological and clinical severity in these genetic FTLD subtypes.
- In vivo iron imaging (T2*-weighted MRI, quantitative susceptibility mapping) may serve as a noninvasive marker for FTLD pathology.

